08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Dickkopf homolog 1 (DKK1)

Infectious disease INDICATION: Leishmaniasis; asthma Mouse studies suggest DKK1 inhibitors could help treat allergic asthma and cutaneous leishmaniasis. Blood levels of DKK1 were higher in a mouse model of dust mite allergen-induced asthma than in...
07:00 , Jun 20, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Dickkopf homolog 1 (DKK1) Cell culture studies suggest inhibiting DKK1 could help treat atherosclerosis. Endothelial-to-mesenchymal transition contributes to calcification and fibrosis in atherosclerosis....
08:00 , Dec 8, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Dickkopf homolog 1 (DKK1) Studies in mice suggest DKK1 vaccination could help treat MM. In a mouse model of MM, injection of...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Company News

MorphoSys, Novartis deal

MorphoSys received an undisclosed double-digit million Euro milestone payment from Novartis under a 2007 deal that gave Novartis preferred exclusive access to MorphoSys' HuCAL antibody technology. The payment was triggered by the installation of the...
07:00 , Jul 13, 2009 |  BC Week In Review  |  Company News

MorphoSys, Novartis deal

MorphoSys AG (Xetra:MOR), Martinsried, Germany   Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Business: Antibodies   The partners' 2007 antibody deal will now run until 2017, after Morphosys met the predetermined technology improvement goals, including...
01:04 , Jul 7, 2009 |  BC Extra  |  Company News

MorphoSys, Novartis deal to run through 2017

MorphoSys AG (Xetra:MOR) said a clause in a 2007 antibody deal allowing Novartis AG (NYSE:NVS; SIX:NOVN) to terminate the collaboration after seven years was removed because MorphoSys met predetermined technology improvement goals, including the release...